MRI and genetic data find no independent risk from hypertrabeculation
A team from the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), working with a large international network of hospitals and research centers, has shown that left ventricular hypertrabeculation—an anatomical feature of the heart long associated with poor prognosis—does not lead to worse outcomes in patients with dilated cardiomyopathy.
A large study of 1,160 patients with dilated cardiomyopathy has found that left ventricular hypertrabeculation, a key feature linked to poor prognosis, does not affect patient outcomes. Led by Dr. Pablo García-Pavía, researchers from the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and a global network of hospitals discovered no increased risk of embolic events, heart failure, or severe arrhythmias in patients with hypertrabeculation.
The study, published in Circulation, suggests hypertrabeculation should be viewed as an anatomical trait rather than a distinct disease requiring specific treatment. Historically, hypertrabeculation was classified as a separate condition, but this research confirms it is an anatomical characteristic of dilated cardiomyopathy. Factors like ejection fraction, myocardial fibrosis, and genetic alterations proved to be the primary predictors of prognosis, leaving hypertrabeculation without independent risk or therapeutic implications.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
